ALX Oncology Reports Encouraging Clinical Data of Evorpacept

– Twenty patients with indolent (n=18) and aggressive (n=2) R/R B-NHL received evorpacept plus standard rituximab and lenalidomide (“R2”)

Related Keywords

Texas , United States , American , Caitlyn Doherty , Sophia Randolph , Oncology Holdings Inc , Corporate Communications , University Of Texas Md Anderson Cancer Center , Exchange Commission , American Association For Cancer Research , Company Nasdaq , Development Pillars , Md Anderson Cancer Center , American Cancer Society , Holdings Inc , Cancer Research , Paolo Strati , Assistant Professor , Chief Medical Officer , Oral Presentation , Clinical Trials Minisymposium , Novel Agents , Emerging Therapeutic , Evorpacept Combination , Unique Profile , Rational Design , Dual Development , Refractory Indolent , Cancer Facts , Annual Reports , Quarterly Reports , Media Contact , Investor Relations , Region ,